Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a price target of $17.
August 09, 2023 | 8:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals and maintained a price target of $17.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $17 price target could potentially boost investor confidence in Recursion Pharmaceuticals, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100